Journal of pediatric gastroenterology and nutrition · 2025
Subcutaneous infliximab use in children with inflammatory bowel disease in an Australian center.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Eldredge Jessica A, Kaur Rajneesh, Chua Cher Wei, Chidgey Trudy, Tano Michelle, Singh Noel, Barclay Peter, Magoffin Annabel, Thacker Kunal, Dutt Shoma, O'Loughlin Edward V
Аннотация
OBJECTIVES: Experience with subcutaneous infliximab (SC-IFX) use in pediatric inflammatory bowel disease (IBD) remains limited. We aimed to evaluate the clinical efficacy, tolerability, and cost-benefit of SC-IFX as a treatment for children with IBD in a real-world setting.
METHODS: A prospective, single-center cohort study was conducted at the Children's Hospital at Westmead, Australia, from February to June 2024. Thirty-three children aged 8-18 years with established IBD commenced SC-IFX (120 mg fortnightly). Assessments included clinical disease activity indices (Pediatric Crohn's Disease Activity Index [PCDAI]/Pediatric Ulcerative Colitis Activity Index [PUCAI]), biochemical markers, and infliximab levels. Patient experience was assessed via questionnaires on quality-of-life (QOL) and treatment satisfaction.
RESULTS: Thirty-one (31/33) children completed treatment over a 12-week follow-up period. Median infliximab levels increased from 7.8 ug/mL (interquartile range [IQR]: 5.7-11) at baseline to 19.6 ug/mL (IQR: 13.2-21.8) at Week 12 (p < 0.001). Serum infliximab level >20 ug/mL was seen in 48% of children at Week 12. Minimal change was observed in fecal calprotectin and clinical disease activity indices. High satisfaction rates with improved patient and caregiver QOL are described. Cost analyses indicated a potential for net institutional savings. Drug continuation was planned in 85% (28/33) following the 12-week study period.
CONCLUSIONS: Our experience suggests SC-IFX may be an effective and well-tolerated alternative to intravenous infliximab (IV-IFX) in pediatric IBD. Median serum infliximab levels increased across over the study period. Use of SC-IFX may offer a positive impact on patient and caregiver QOL, along with resource and cost saving benefits for healthcare systems. Larger-scale studies are needed to validate these findings and optimize treatment protocols.
METHODS: A prospective, single-center cohort study was conducted at the Children's Hospital at Westmead, Australia, from February to June 2024. Thirty-three children aged 8-18 years with established IBD commenced SC-IFX (120 mg fortnightly). Assessments included clinical disease activity indices (Pediatric Crohn's Disease Activity Index [PCDAI]/Pediatric Ulcerative Colitis Activity Index [PUCAI]), biochemical markers, and infliximab levels. Patient experience was assessed via questionnaires on quality-of-life (QOL) and treatment satisfaction.
RESULTS: Thirty-one (31/33) children completed treatment over a 12-week follow-up period. Median infliximab levels increased from 7.8 ug/mL (interquartile range [IQR]: 5.7-11) at baseline to 19.6 ug/mL (IQR: 13.2-21.8) at Week 12 (p < 0.001). Serum infliximab level >20 ug/mL was seen in 48% of children at Week 12. Minimal change was observed in fecal calprotectin and clinical disease activity indices. High satisfaction rates with improved patient and caregiver QOL are described. Cost analyses indicated a potential for net institutional savings. Drug continuation was planned in 85% (28/33) following the 12-week study period.
CONCLUSIONS: Our experience suggests SC-IFX may be an effective and well-tolerated alternative to intravenous infliximab (IV-IFX) in pediatric IBD. Median serum infliximab levels increased across over the study period. Use of SC-IFX may offer a positive impact on patient and caregiver QOL, along with resource and cost saving benefits for healthcare systems. Larger-scale studies are needed to validate these findings and optimize treatment protocols.